Alcon Laboratories, Inc.

Alcon Manufacturing, Ltd.

Alcon Laboraties, Inc.

Alcon Research, Ltd.

Verney L Sallee

Peter G Klimko

Paul W Zinke

Louis DeSantis, Jr

Mark R Hellberg

John E Bishop

Thomas R Dean

Louis M Desantis, Jr

Robert D Selliah

Jesse Albert May

George E Barnes

Manoj L Maniar

Michael L Chandler

Tom R Dean

Louis M DeSantis

Marsha A McLaughlin

Louis Desantis Jr

Disclosed is the use of cloprostenol and fluprostenol analogues in combination with carbonic anhydrase inhibitors for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor.

Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension

A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:

11-halo prostaglandins for the treatment of glaucoma or ocular hypertension

15-ketal postaglandins for the treatment of glaucoma or ocular hypertension

Substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.

Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives

Disclosed is the use of cloprostenol and fluprostenol analogues and combinations thereof with other medicaments for the treatment of glaucoma and ocular hypertension and ophthalmic compositions therefor. Also disclosed are methods of treating optic nerve disorders using the cloprostenol and fluprostenol analogues.

Compositions containing DP-agonist and FP-agonists prostaglandin agonists and methods of their use in treating glaucoma or ocular hypertension are disclosed.

Combinations of DP and FP type prostaglandins for lowering IOP

Substituted tetrahydrofuran analogs of F-series prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.

substituted tetrahydrofuran analogs of prostaglandins as ocular

Disclosed is the use of cloprostenol and fluprostenol analogues for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.

Use of cloprostenol and fluprostenol analogues to treat glaucoma and

Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.

Combinations of prostaglandins and clonidine derivatives for the

9-Halo-13,14-dihydroprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and

The use of certain dopaminergic compounds for controlling elevations of intraocular pressure is disclosed. The compounds are ergoline derivatives. The most preferred compound is cabergoline. The compounds have been found to produce a significant reduction of intraocular pressure.

Use of cabergoline and related ergoline derivatives for controlling

Compositions containing 3-Oxa-D-prostaglandins and methods of their use in treating glaucoma or ocular hypertension are disclosed.

3-Oxa-D-prostaglandins for lowering IOP

Cloprostenol and fluprostenol analogues and their use to treat glaucoma

9-Haloprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Growing community of inventors

Burleson, TX, United States of America

Verney L Sallee